Home > Oncology > Trastuzumab deruxtecan slashes disease progression, death by 72% in HER-2+ breast cancer

Trastuzumab deruxtecan slashes disease progression, death by 72% in HER-2+ breast cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The New England Journal of Medicine
Reuters Health - 23/03/2022 - Treatment with trastuzumab deruxtecan reduces the risk of disease progression and death by 72% over 12 months compared with trastuzumab emtansine therapy among women with HER2-positive metastatic breast cancer, according to interim phase 3 results from the DESTINY-Breast03 trial. About two million people are diagnosed with breast cancer worldwide each year and roughly one in five tumors is HER2 positive. The new test involved 524 volunteers with unresectable or metastatic breast cancer who had previously been treated with trastuzumab and a taxane. Patients with brain metastases that were symptomatic or required treatment were excluded. The drugs were given intravenously every three weeks. The rate of survival without disease progression after one year was 75.8% with trastuzumab deruxtecan and 34.1% with trastuzumab emtansine, Dr. Javier Cortes of the International Breast Cancer Center in Barcelona, Spain, and colleagues report in...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on